Literature DB >> 3158275

Pharmacokinetics of ciprofloxacin after oral and parenteral administration.

G Höffken, H Lode, C Prinzing, K Borner, P Koeppe.   

Abstract

In 12 fasting volunteers, the pharmacokinetics of ciprofloxacin (Bay o 9867; 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinoline carbonic acid) were determined after the administration of 50, 100, and 750 mg orally as well as 50 and 100 mg intravenously over 15 min. Serum and urine concentrations were detected with a bioassay. In addition, urine concentrations after a 50-mg dosing were measured by high-pressure liquid chromatography. The serum course of ciprofloxacin could best be described by an open three-compartment model. High volumes of distribution (exceeding 200 liters/100 kg) suggested effective diffusions in the extravascular space. The terminal half-life of ciprofloxacin ranged between 3 and 4 h. High total and renal clearances suggested additional elimination pathways, such as tubular secretion, metabolism, or biliary excretion. After oral administration, absorption was sufficient, and the absolute bioavailability varied between 0.77 and 0.63. Maximal serum concentrations were attained 0.5 to 1 h after dosing; the higher dosage tended towards a delay in absorption. The proportion of the relative amount of metabolites to the total amount of drug excreted in urine increased from 29.7% after intravenous administration to 42.7% after oral dosing, indicating a first-pass effect of the liver. Ciprofloxacin concentrations with a bioassay were 3 to 27% higher than with high-pressure liquid chromatography, which may indicate the presence of biologically active metabolites. No side effects were recorded.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3158275      PMCID: PMC176280          DOI: 10.1128/AAC.27.3.375

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Pharmacokinetics and tissue penetration of ciprofloxacin.

Authors:  B Crump; R Wise; J Dent
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

2.  Determination of apalcillin and its metabolites in human body fluids by high-pressure liquid chromatography.

Authors:  K Borner; H Lode; A Elvers
Journal:  Antimicrob Agents Chemother       Date:  1982-12       Impact factor: 5.191

3.  Effect of route of administration and distribution on drug action.

Authors:  L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1978-12

4.  A program for non-linear regression analysis to be used on desk-top computers.

Authors:  P Koeppe; C Hamann
Journal:  Comput Programs Biomed       Date:  1980-12

5.  Estimating the fraction reabsorbed in drugs undergoing enterohepatic circulation.

Authors:  F L Tse; F Ballard; J Skinn
Journal:  J Pharmacokinet Biopharm       Date:  1982-08

6.  In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent.

Authors:  G M Eliopoulos; A Gardella; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

7.  Pharmacokinetic interpretation of the enterohepatic recirculation and first-pass elimination of morphine in the rat.

Authors:  B E Dahlström; L K Paalzow
Journal:  J Pharmacokinet Biopharm       Date:  1978-12

8.  Comparative in vitro activity of ciprofloxacin against Campylobacter spp. and other bacterial enteric pathogens.

Authors:  L J Goodman; R M Fliegelman; G M Trenholme; R L Kaplan
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

9.  In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid.

Authors:  A Bauernfeind; C Petermüller
Journal:  Eur J Clin Microbiol       Date:  1983-04       Impact factor: 3.267

10.  Norfloxacin disposition after sequentially increasing oral doses.

Authors:  B N Swanson; V K Boppana; P H Vlasses; H H Rotmensch; R K Ferguson
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

View more
  95 in total

1.  The disposition kinetics, urinary excretion and dosage regimen of ciprofloxacin in buffalo calves (Bubalus bubalis).

Authors:  S P Saini; A K Srivastava
Journal:  Vet Res Commun       Date:  2001-12       Impact factor: 2.459

2.  Pharmacokinetics of FCE 22891, a new oral penem.

Authors:  A Saathoff; H Lode; B Hampel; K M Deppermann; K Borner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

3.  Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole.

Authors:  M Boeckh; H Lode; K M Deppermann; S Grineisen; F Shokry; R Held; K Wernicke; P Koeppe; J Wagner; C Krasemann
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

Review 4.  Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials.

Authors:  A Aminimanizani; P Beringer; R Jelliffe
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

5.  Continuous Intestinal Absorption Model Based on the Convection-Diffusion Equation.

Authors:  Swati Nagar; Richard C Korzekwa; Ken Korzekwa
Journal:  Mol Pharm       Date:  2017-07-31       Impact factor: 4.939

Review 6.  Quinolones in Salmonella typhi infection.

Authors:  H L DuPont
Journal:  Drugs       Date:  1993       Impact factor: 9.546

7.  Organic anion transporter 3 (oat3/slc22a8) interacts with carboxyfluoroquinolones, and deletion increases systemic exposure to ciprofloxacin.

Authors:  Adam L Vanwert; Chutima Srimaroeng; Douglas H Sweet
Journal:  Mol Pharmacol       Date:  2008-04-01       Impact factor: 4.436

Review 8.  Complicated catheter-associated urinary tract infections due to Escherichia coli and Proteus mirabilis.

Authors:  S M Jacobsen; D J Stickler; H L T Mobley; M E Shirtliff
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

9.  A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities.

Authors:  A A Firsov; S N Vostrov; A A Shevchenko; Y A Portnoy; S H Zinner
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

10.  MIC-based interspecies prediction of the antimicrobial effects of ciprofloxacin on bacteria of different susceptibilities in an in vitro dynamic model.

Authors:  A A Firsov; S N Vostrov; A A Shevchenko; S H Zinner; G Cornaglia; Y A Portnoy
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.